Literature DB >> 19942263

Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing.

David G Bostwick1, Junqi Qian, Krystyna Drewnowska, Stephen Varvel, Kathleen C Bostwick, Michael Marberger, Roger S Rittmaster.   

Abstract

OBJECTIVES: To compare biopsy quality factors among study sites worldwide at entry and at year 2 in the reduction by dutasteride of prostate cancer events study. The accuracy of prostate cancer detection is influenced by the length and number of biopsy cores.
METHODS: Biopsy quality factors at entry and at year 2 were compared for subjects enrolled from 6 geographic regions: North America, South America, Western Europe, Central/Eastern Europe, Australia, and Africa. Investigator training was provided for prostate biopsy collection before year 2, emphasizing core length and number of cores obtained.
RESULTS: Data were collected prospectively from 4649 subjects at entry and 6267 subjects at year 2. At entry, the aggregate length, number of cores, and mean length of cores differed significantly among regions. Aggregate length was longest in biopsies from Australia, and number of cores was highest from South America. At year 2, each region collected the protocol-required 10 cores, and aggregate length and mean length of cores were greater than for entry biopsies; site variance was reduced for all factors.
CONCLUSIONS: There were significant differences in aggregate length, number of cores, and mean length of cores among regions at study entry. After investigator training by the study sponsor and use of a central laboratory for standardized processing, year 2 biopsies showed an increase in all 3 quality factors when compared with entry biopsies. Variance in biopsy quality can be reduced by investigator training and standardization of collection and processing, thereby optimizing detection of cancer. Biopsy quality may be a useful comparative measure in urologic practice. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942263     DOI: 10.1016/j.urology.2009.07.1348

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Gleason underestimation is predicted by prostate biopsy core length.

Authors:  Leonardo O Reis; Brunno C F Sanches; Gustavo Borges de Mendonça; Daniel M Silva; Tiago Aguiar; Ocivaldo P Menezes; Athanase Billis
Journal:  World J Urol       Date:  2014-08-02       Impact factor: 4.226

2.  Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Authors:  T Van der Kwast; L Bubendorf; C Mazerolles; M R Raspollini; G J Van Leenders; C-G Pihl; P Kujala
Journal:  Virchows Arch       Date:  2013-08-06       Impact factor: 4.064

3.  Length of prostate biopsies is not necessarily compromised by pooling multiple cores in one paraffin block: an observational study.

Authors:  Teemu T Tolonen; Jorma Isola; Antti Kaipia; Jarno Riikonen; Laura Koivusalo; Sanna Huovinen; Marita Laurila; Sinikka Porre; Mika Tirkkonen; Paula Kujala
Journal:  BMC Clin Pathol       Date:  2015-03-08

4.  Use of Prospective Multiplex Immunohistochemistry to Redefine Tissue Pathways of Diagnostic Core Biopsy of Prostate.

Authors:  Teresa Thomas; Sarah Wedden; Naveed Afzal; John Mikel; Corrado D'Arrigo
Journal:  Appl Immunohistochem Mol Morphol       Date:  2022-09-06

Review 5.  Focal low-dose rate brachytherapy for the treatment of prostate cancer.

Authors:  William Y Tong; Gilad Cohen; Yoshiya Yamada
Journal:  Cancer Manag Res       Date:  2013-09-13       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.